



Dr. Murray Ratcliffe joins as TheraCarb Chief Operating Officer

(CALGARY, November 6) – Thanks to a pilot program provided by the Alberta Heritage Foundation for Medical Research (AHFMR) that enables companies to recruit top talent in the biotech field, TheraCarb is very pleased to welcome R. Murray Ratcliffe, Ph.D. as its Chief Operating Officer. Murray Ratcliffe joins TheraCarb from RMR Consulting and brings 25 years of management experience in the biotech/pharma industry in the United States and Canada. This includes prominent roles as Chief Technology Officer (Cytovax Biotechnologies, Edmonton), VP R&D and Manufacturing (Synsorb Biotech, Calgary) and Director of Chemistry (Cytel Corp, San Diego).

“We are delighted to have Murray join us as COO, at such an important time in the company’s development” says Dr. Mary Earle, President & CEO of TheraCarb. “We look forward to his leadership in this role”. Dr. Ratcliffe’s is the inaugural recruitment supported by the Senior Recruitment Health Industry Award (SRHIA), a new initiative offered through the ForeFront Program, AHFMR’s commercialization unit.

Dr. Ratcliffe has successfully managed drug development projects from early stage research through to late stage development. He has extensive experience in carbohydrate chemistry and has also managed projects involving vaccine, peptide and monoclonal antibody drug candidates. Other key roles have involved process development and scale-up, facility design and operations, CMC submissions, patent portfolio management and interaction with regulatory bodies. “I am very pleased with the opportunity to join TheraCarb and look forward to contributing to its continuing success,” says Dr. Ratcliffe.

About TheraCarb:

TheraCarb Inc. is an Alberta-based biotechnology company developing medicines for diseases with no known cure. With a vaccine and drug platform technology the company is focused on pre-clinical and early clinical proof of concept studies, developing late stage products through partnerships. TheraCarb’s lead vaccine candidate is designed to treat infections from *Candida albicans*, and is being advanced through a strategic alliance with Wellstat Vaccines (Gaithersburg, MA).

About the Alberta Heritage Foundation for Medical Research’s ForeFront Program:

AHFMR’s ForeFront program supports people at all levels of expertise in the biotechnology sector and aims to build industry capacity and accelerate the commercialization of evidence-based research. The ForeFront Program offers a number of awards to assist people gain first-hand experience and advance their careers in order to help develop Alberta’s next-generation economy.

For more information contact:

Sanah Jowhari
TheraCarb Inc.
(403) 282-2030
sanah@theracarb.com
www.theracarb.com

Carla Weyland
ForeFront, AHFMR
(780) 429-9331
carla.weyland@ahfmr.ab.ca
www.ahfmr.ab.ca